GlaxoSmithKline and Sanofi: a partnership we didn’t think we would see

GlaxoSmithKline and Sanofi: a partnership we didn’t think we would see

The biggest European pharmaceutical companies started collaborating to develop a vaccine against the novel COVID-19. The first batch is said to be ready in the next 20 months.

It seems that Coronavirus brings rivals together as an example of how drug-makers should team up and fight the common threat. The partnership is unprecedented, but it makes sense as the companies are complementary as far as the missing pieces from the vaccine are concerned.

A joint statement emerged on Tuesday mentioning Phase 1 of trials, which implies human testing. It can happen in the second half of this year. If everything goes according to plan, the vaccine will probably be available by the second half of the next year.

What this partnership is all about is combining an experimental Sanofi vaccine that’s missing one ingredient. GSK will provide the component – an adjuvant made from oil and water meant to boost the antigen, the central part of the vaccine. GSK is well-known for its capacity to make such adjuvants since 2009’s H1N1 swine flu outbreak. The ingredient will make the vaccine more effective when administrated in lower doses, and it facilitates mass production.

Emma Walmsley, CEO of GSK, stated that usually, a vaccine takes a decade to develop and test. But given the current situation, they accelerated the process to 18 months.

The race to find a treatment or a vaccine against the novel virus is tight, as other pharmaceutical giants are making progress. Gilead already has a potential medicine in trials with 1,000 patients with moderate and severe symptoms. It represents Phase 3 of a study, and even WHO said that it can be the "the only drug right now that we think may have efficacy."

Pfizer identified an antiviral that "if successful, would be given early in the disease process when patients are admitted to the hospital," the company's chief scientific officer, Mikael Dolsten said in a statement last week.

Human clinical trials started yesterday in China, with two potential vaccines that are in testing. Local pharmaceutical companies Sinopharm and Sinovac Biotech developed the two potential vaccines.


See the difference when investing with Capex by accessing elite features:

• Stellar custom service

• Powerful WebTrader platform and mobile app

• High-end integrated trading tools

Stay tuned for more! Register now!


Sources: bbc.com, cnbc.com, ft.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation. Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.